José L Blanco1, Anne-Geneviéve Marcelin2,3, Christine Katlama2,4, Esteban Martinez1. 1. Infectious Diseases Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain. 2. Sorbonne University, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136). 3. Service de Virologie, APHP Hôpital Pitié-Salpêtrière. 4. Service de Maladies Infectieuses et Tropicale, APHP Hôpital Pitié-Salpêtrière, Paris, France.
Abstract
PURPOSE OF REVIEW: Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (InSTI) with an outstanding antiviral potency, good tolerability, good pharmacokinetic profile with a lack of major drug-drug interactions, and a barrier to resistance higher than the other compounds of the class (raltegravir and elvitegravir) and allegedly as high as that of boosted protease inhibitors. For these reasons, DTG, after successful results in a context of triple therapy in various clinical scenarios, has been investigated mostly by independent investigators in less-drug regimens, including dolutegravir monotherapy, in the context of a growing clinical interest for adjusting successful antiretroviral therapy to the increasing number of limitations for standard antiretroviral therapy in some HIV-infected patients. However, the development of genotypic resistance in case of failure to DTG monotherapy was unexpected. RECENT FINDINGS: Data on efficacy and resistance from preclinical studies, randomized clinical trials and clinical cohorts of HIV-infected patients treated with DTG monotherapy published in indexed journals or presented at international meetings were reviewed. SUMMARY: Monotherapy with dolutegravir has a high rate for resistance selection in the integrase gene through different pathways in case of virological failure.
PURPOSE OF REVIEW: Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (InSTI) with an outstanding antiviral potency, good tolerability, good pharmacokinetic profile with a lack of major drug-drug interactions, and a barrier to resistance higher than the other compounds of the class (raltegravir and elvitegravir) and allegedly as high as that of boosted protease inhibitors. For these reasons, DTG, after successful results in a context of triple therapy in various clinical scenarios, has been investigated mostly by independent investigators in less-drug regimens, including dolutegravir monotherapy, in the context of a growing clinical interest for adjusting successful antiretroviral therapy to the increasing number of limitations for standard antiretroviral therapy in some HIV-infectedpatients. However, the development of genotypic resistance in case of failure to DTG monotherapy was unexpected. RECENT FINDINGS: Data on efficacy and resistance from preclinical studies, randomized clinical trials and clinical cohorts of HIV-infectedpatients treated with DTG monotherapy published in indexed journals or presented at international meetings were reviewed. SUMMARY: Monotherapy with dolutegravir has a high rate for resistance selection in the integrase gene through different pathways in case of virological failure.
Authors: Emily P Hyle; Justine A Scott; Paul E Sax; Lucia R I Millham; Caitlin M Dugdale; Milton C Weinstein; Kenneth A Freedberg; Rochelle P Walensky Journal: Clin Infect Dis Date: 2020-03-17 Impact factor: 9.079
Authors: Kate El Bouzidi; Steven A Kemp; Rawlings P Datir; Fati Murtala-Ibrahim; Ahmad Aliyu; Vivian Kwaghe; Dan Frampton; Sunando Roy; Judith Breuer; Caroline A Sabin; Obinna Ogbanufe; Man E Charurat; David Bonsall; Tanya Golubchik; Christophe Fraser; Patrick Dakum; Nicaise Ndembi; Ravindra K Gupta Journal: J Antimicrob Chemother Date: 2020-06-01 Impact factor: 5.790
Authors: Kim Steegen; Gert van Zyl; Esrom Letsoalo; Mathilda Claassen; Lucia Hans; Sergio Carmona Journal: Open Forum Infect Dis Date: 2019-08-21 Impact factor: 3.835
Authors: Kirsten L White; Nathan Osman; Ernesto Cuadra-Foy; Bluma G Brenner; Devleena Shivakumar; Federico Campigotto; Manuel Tsiang; Philip A Morganelli; Nikolai Novikov; Scott E Lazerwith; Haolun Jin; Anita Niedziela-Majka Journal: Antimicrob Agents Chemother Date: 2021-03-01 Impact factor: 5.191